Collegium Pharmaceutical, Inc. $COLL Shares Sold by Advantage Alpha Capital Partners LP

Advantage Alpha Capital Partners LP decreased its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 18.9% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 15,531 shares of the specialty pharmaceutical company’s stock after selling 3,630 shares during the quarter. Advantage Alpha Capital Partners LP’s holdings in Collegium Pharmaceutical were worth $459,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Millennium Management LLC grew its position in Collegium Pharmaceutical by 248.5% during the first quarter. Millennium Management LLC now owns 647,832 shares of the specialty pharmaceutical company’s stock valued at $19,338,000 after buying an additional 461,914 shares during the period. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Collegium Pharmaceutical during the 1st quarter valued at about $3,085,000. Jane Street Group LLC increased its stake in shares of Collegium Pharmaceutical by 218.7% in the 1st quarter. Jane Street Group LLC now owns 131,520 shares of the specialty pharmaceutical company’s stock valued at $3,926,000 after purchasing an additional 90,255 shares in the last quarter. Nuveen LLC acquired a new position in Collegium Pharmaceutical in the 1st quarter worth about $2,674,000. Finally, Tejara Capital Ltd boosted its position in Collegium Pharmaceutical by 288.4% during the first quarter. Tejara Capital Ltd now owns 111,792 shares of the specialty pharmaceutical company’s stock worth $3,337,000 after purchasing an additional 83,011 shares in the last quarter.

Analyst Ratings Changes

COLL has been the topic of a number of research analyst reports. Wall Street Zen raised shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Needham & Company LLC reiterated a “buy” rating and issued a $46.00 target price on shares of Collegium Pharmaceutical in a research report on Tuesday, October 28th. HC Wainwright upped their price target on shares of Collegium Pharmaceutical from $44.00 to $46.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. Truist Financial raised their price target on shares of Collegium Pharmaceutical from $45.00 to $48.00 and gave the company a “buy” rating in a research note on Friday, November 7th. Finally, Zacks Research upgraded Collegium Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research note on Friday, November 21st. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $44.25.

Collegium Pharmaceutical Price Performance

Shares of COLL stock opened at $46.23 on Friday. The company has a debt-to-equity ratio of 2.71, a current ratio of 1.36 and a quick ratio of 1.27. The company has a market capitalization of $1.46 billion, a PE ratio of 28.71 and a beta of 0.61. The firm’s 50-day moving average is $37.88 and its two-hundred day moving average is $34.53. Collegium Pharmaceutical, Inc. has a 12 month low of $23.23 and a 12 month high of $48.18.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Wednesday, September 4th. The specialty pharmaceutical company reported $1.26 EPS for the quarter. The company had revenue of $135.55 million for the quarter. Collegium Pharmaceutical had a return on equity of 102.03% and a net margin of 7.72%. Analysts predict that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current year.

Insider Buying and Selling at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, CFO Colleen Tupper sold 30,000 shares of the business’s stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $40.53, for a total value of $1,215,900.00. Following the completion of the transaction, the chief financial officer owned 126,667 shares in the company, valued at $5,133,813.51. The trade was a 19.15% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 2.51% of the company’s stock.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.